RESUMEN
On the basis of the good anti-inflammatory properties shown by the 9-alkyl-N,N-dialkyl-5-(alkylamino)[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides 1, a series of analogues of such compounds, in which the 9-alkyl substituent was replaced by an ester or amide group (compounds 3a-i), was prepared and tested (inhibition of carrageenan-induced paw edema in the rat). Also two 5-(N-alkyl,N-acylamino) derivatives (compounds 4a,b) were synthesized and evaluated for the same purpose. Even though the general trend for these new [1,2,4]triazolo[4,3-a][1,8]naphthyridine derivatives was a decrease in activity compared with compounds 1, some of the new synthesized compounds exhibited still good anti-inflammatory properties.
Asunto(s)
Antiinflamatorios/síntesis química , Antiinflamatorios/farmacología , Naftiridinas/química , Triazoles/síntesis química , Triazoles/farmacología , Animales , Antiinflamatorios/química , Antiinflamatorios/uso terapéutico , Carragenina/toxicidad , Diseño de Fármacos , Edema/inducido químicamente , Edema/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Masculino , Ratas , Ratas Sprague-Dawley , Triazoles/química , Triazoles/uso terapéuticoRESUMEN
The [1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamide derivatives 5-amino (2) or 5-alkoxy (3) substituted and the 5-amino[1,2,4]triazolo[4,3-a]quinoline-4-carboxamide derivatives (4), designed to obtain new effective analgesic and/or anti-inflammatory agents were synthesized. Ten compounds 2 and 4 showed an interesting analgesic activity: the most potent ones are 2j (36% inhibition, P<0.05) and 4b (77% inhibition, P<0.01) at 6.25 and 25 mg kg(-1) doses, respectively. Compounds 2i-l and 4c showed notable anti-inflammatory properties: the most potent ones are 2i (68% inhibition, P<0.01) and 2l (42% inhibition, P<0.05) at 12.5 and 6.25 mg kg(-1) doses, respectively. The replacement in compounds 2 of the N-substituted 5-amino substituents with similar alkoxy groups usually afforded less active compounds 3.
Asunto(s)
Amidas/química , Aminas/química , Analgésicos/síntesis química , Antiinflamatorios/síntesis química , Danazol/química , Naftiridinas/síntesis química , Enfermedad Aguda , Analgésicos/química , Analgésicos/farmacología , Animales , Antiinflamatorios/química , Antiinflamatorios/farmacología , Femenino , Masculino , Ratones , Estructura Molecular , Actividad Motora/efectos de los fármacos , Naftiridinas/química , Naftiridinas/farmacología , Ratas , Gastropatías/inducido químicamente , Relación Estructura-ActividadRESUMEN
The synthesis and in vitro antiplatelet activity significant data of coumarin derivatives 5i-x and quinolin-2(1H)-one derivatives 22a,b, as well as the corresponding structure-activity relationships are described. The recently reported 8-methyl-4-(1-piperazinyl)-7-(3-pyridylmethoxy)coumarin 5f and its potent 7-(2-morpholinoethoxy)-substituted new analogue 5u were notably more effective inhibitors of pure human platelet PDE3 than milrinone and cilostazol: these data were related, through a molecular modeling study, with the molecular interactions of the four compounds with the human PDE3A catalytic site.
Asunto(s)
3',5'-AMP Cíclico Fosfodiesterasas/antagonistas & inhibidores , Cumarinas/síntesis química , Morfolinas/síntesis química , Inhibidores de Fosfodiesterasa/síntesis química , Piperazinas/síntesis química , Inhibidores de Agregación Plaquetaria/síntesis química , 3',5'-AMP Cíclico Fosfodiesterasas/sangre , 3',5'-AMP Cíclico Fosfodiesterasas/química , Dominio Catalítico , Cumarinas/química , Cumarinas/farmacología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3 , Humanos , Técnicas In Vitro , Modelos Moleculares , Morfolinas/química , Morfolinas/farmacología , Inhibidores de Fosfodiesterasa/química , Inhibidores de Fosfodiesterasa/farmacología , Piperazinas/química , Piperazinas/farmacología , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/farmacologíaRESUMEN
Most N,N-disubstituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides 9 (compounds 9a, c-i) and the N-monosubstituted one 8c were obtained by treating with excess amine the corresponding 5-chloroderivative 7a, which was in turn prepared by cyclocondensation of the 2,4-dichloro-N,N-diethyl-1,8-naphthyridine-3-carboxamide (4a) with isobutyrohydrazide. Compounds 8a,b and 9b,j-m were obtained according with the methods shown in Scheme 1. The above now synthesized compounds, along with the previously described 8d and 8e, were tested for their anti-inflammatory, analgesic and antipyretic properties, and most compounds also for their effect on spontaneous mice locomotor activity and their acute gastrolesivity in rats. Several compounds showed potent anti-inflammatory and/or analgesic activities, and all the compounds tested proved to be completely lacking in acute gastrolesivity. In many cases compounds 8 and 9 produced hypothermic effect, usually at high doses. On the whole, the N-monosubstituted 5-aminoderivatives 8 appeared to be more potent anti-inflammatory agents than the corresponding N,N-disubstituted 9, whereas these latter compounds exhibited higher analgesic activity.
Asunto(s)
Analgésicos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Naftiridinas/uso terapéutico , Úlcera Gástrica/prevención & control , Analgésicos/efectos adversos , Analgésicos/química , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/química , Relación Dosis-Respuesta a Droga , Fiebre/tratamiento farmacológico , Hipotermia/inducido químicamente , Actividad Motora/efectos de los fármacos , Naftiridinas/efectos adversos , Naftiridinas/química , Ratas , Úlcera Gástrica/inducido químicamente , Relación Estructura-ActividadRESUMEN
The effect on human platelets of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414) was tested in vitro by measuring aggregation induced by several agonists, cAMP and cGMP levels, cAMP phosphodiesterase and PKC activities and [Ca2+]i. The RC414 effect on nitric oxide production was also evaluated. RC414 in a dose-dependent manner inhibited aggregation both in platelet rich plasma and in washed platelets. It was particularly effective in platelets challenged by collagen, ADP and thrombin: IC50 values are 0.51 +/- 0.12 microM, 0.98 +/- 0.36 microM and 1.00 +/- 0.15 microM, respectively. RC414 increased cAMP levels, through the specific inhibition of the cAMP high affinity phosphodiesterase (IC50 = 1.73 +/- 0.35 microM). RC414 reduced [Ca2+]i transients and PKC activation induced by thrombin. In addition RC414 was able to increase nitric oxide formation involving the stimulation of constitutive nitric oxide synthase enzyme. In conclusion, RC414 exerts its powerful anti-platelet activity by increasing cAMP intracellular levels and nitric oxide formation.
Asunto(s)
Calcio/metabolismo , Cromonas/farmacología , AMP Cíclico/metabolismo , Piperazinas/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , 3',5'-AMP Cíclico Fosfodiesterasas/metabolismo , Arginina/farmacología , Plaquetas/efectos de los fármacos , Plaquetas/fisiología , Cromonas/química , GMP Cíclico/metabolismo , Interacciones Farmacológicas , Humanos , Técnicas In Vitro , Óxido Nítrico/metabolismo , Piperazinas/química , Proteína Quinasa C/metabolismo , Trombina/farmacologíaRESUMEN
Pursuing our chemical and biological studies in this field, we described the multistep preparation of the new 5-, 6-, or 7-alkoxy and 7-alkoxy-8-methyl substituted 4-(1-piperazinyl)coumarins 5d-v, as well as the in vitro evaluation of their inhibitory activity on human platelet aggregation induced in platelet-rich plasma by ADP, collagen or the Ca(2+) ionophore A23187. Compounds 5h-j,p,r-u showed notably high activity towards all the platelet aggregation inducers used, and the most active one, 8-methyl-4-(1-piperazinyl)-7-(3-pyridylmethoxy)coumarin (5t), proved to be a potent in vitro antiplatelet agent.
Asunto(s)
Plaquetas/efectos de los fármacos , Cumarinas/síntesis química , Cumarinas/farmacología , Inhibidores de Agregación Plaquetaria/síntesis química , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Adenosina Difosfato/farmacología , Plaquetas/metabolismo , Calcimicina/farmacología , Calcio/farmacología , Colágeno/farmacología , Humanos , Ionóforos/farmacología , Estructura Molecular , Activación Plaquetaria/efectos de los fármacosRESUMEN
The reaction of proper N,N-dialkyl-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines (1) with N-chlorosuccinimide afforded their 4-chloroderivatives 3 which in turn were treated with cyclic amines to give the corresponding 4,5-diaminoderivatives 4. The N,N-dialkyl-4H-imidazo[1,2-a][1,5]benzodiazepin-5-amines (5) were prepared starting from suitable 4-(dialkylamino)-1,3-dihydro-2H-1,5-benzodiazepin-2-ones (8), through multistep synthetic routes. At the 200 mg kg(-1) os dose, some compounds 3 and 4 showed notable analgesic or anti-inflammatory activity but no antipyretic properties, whereas the 5-(dibutylamino) derivatives 5b and 5f proved to be significantly endowed with all these activities. Almost all the compounds 3, 4 and 5 did not show acute toxicity in mice up to 800 mg kg(-1) os dose.
Asunto(s)
Analgésicos no Narcóticos/efectos adversos , Analgésicos no Narcóticos/química , Analgésicos/efectos adversos , Analgésicos/química , Antiinflamatorios/efectos adversos , Antiinflamatorios/química , Benzodiazepinas/efectos adversos , Benzodiazepinas/química , Analgésicos/farmacología , Analgésicos no Narcóticos/farmacología , Animales , Antiinflamatorios/farmacología , Benzodiazepinas/farmacología , Diseño de Fármacos , Fiebre/tratamiento farmacológico , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Ratas , Ratas Wistar , Estómago/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
Various (1E,3E)- and (1Z,3E)-conjugated methylthio derivatives of oxidosqualene (OS) and conjugated and non-conjugated phenylthio derivatives of OS were obtained. These compounds, designed as inhibitors of pig liver and Saccharomyces cerevisiae 2,3-oxidosqualene-lanosterol cyclases (OSC) (EC 5.4.99.7) and of Alicyclobacillus acidocaldarius squalene-hopene cyclase (SHC) (EC 5.4.99.-), contain the reactive function adjacent to carbons involved in the formation of the third and the fourth cycle during OS cyclization. All the new compounds are inhibitors of OSC and SHC, with various degrees of selectivity. The conjugated methylthio derivatives behaved as potent inhibitors of S. cerevisiae OSC, whereas most of the phenylthio derivatives were especially active toward SHC.
Asunto(s)
Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Transferasas Intramoleculares/antagonistas & inhibidores , Escualeno/análogos & derivados , Animales , Bacillaceae/enzimología , Inhibidores Enzimáticos/síntesis química , Concentración 50 Inhibidora , Hígado/enzimología , Estructura Molecular , Saccharomyces cerevisiae/enzimología , Escualeno/química , Relación Estructura-Actividad , Sulfuros/química , Porcinos , Factores de TiempoRESUMEN
The N-substituted tricyclic 2-aminochromone derivatives 1a, 2a, and 2b were obtained by treating the corresponding (methylthio) or (methylsulfinyl) derivatives 10, 11, or 12, respectively, with an excess of the proper amines. Compound 2c was synthesized through the reaction of 2-naphthol with the ethyl N,N-diphenylmalonamate/POCl(3) reagent 14. The N-substituted 4-aminocoumarin bicyclic and tricyclic derivatives 5-8 were prepared by treating the corresponding chloro derivatives with the excess suitable amines. Compounds 1, 2, 5-8 were tested in vitro for their antiproliferative activity (DNA synthesis inhibition in Ehrlich cells) and cytotoxicity (MTT test in HeLa cells). The inhibitory properties of three selected compounds (5c, 5e, 7c) on protein and RNA syntheses in Ehrlich cells were also evaluated. Among the 27 compounds tested, 10 4-aminocoumarin derivatives (5-8) and two 2-aminochromone derivatives (1a and 2a) showed an appreciable antiproliferative activity (IC(50) range: 1.74-13.8 microM), whereas only four compounds 5-8 exhibited a comparable cytotoxic activity (IC(50) range: 4.95-12.9 microM).
Asunto(s)
Cromonas/toxicidad , Cumarinas/toxicidad , Inhibidores de Crecimiento/toxicidad , Piranos/toxicidad , Animales , Carcinoma de Ehrlich/tratamiento farmacológico , Cromonas/química , Cromonas/farmacología , Cumarinas/química , Cumarinas/farmacología , Relación Dosis-Respuesta a Droga , Inhibidores de Crecimiento/química , Inhibidores de Crecimiento/farmacología , Células HeLa , Humanos , Ratones , Piranos/química , Piranos/farmacología , Ensayos Antitumor por Modelo de Xenoinjerto/métodosRESUMEN
On the basis of the very interesting pharmacological properties shown by the 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamide derivatives 1, previously described by us, we have now prepared the 5-aminoimidazo[1,2-a][1,8]naphthyridine-6-carboxamide derivatives 2a-o (a new structural class) whose tricyclic system is isosteric to that of compounds 1. Both compounds 2 and some new properly substituted compounds 1 (1f-k) now synthesized were tested in vivo for their analgesic and anti-inflammatory activities: on the whole, compounds 2 showed notable analgesic properties, whereas many compounds 1 exhibited a very potent anti-inflammatory activity, coupled to scarce analgesic activity. All the effective compounds proved to be completely devoid of acute gastrolesivity (gastric damage) in rats (at the 200 mg kg(-1) oral dose).
Asunto(s)
Analgésicos/química , Analgésicos/farmacología , Antiinflamatorios/química , Antiinflamatorios/farmacología , Naftiridinas/química , Naftiridinas/farmacología , Estómago/efectos de los fármacos , Analgésicos/efectos adversos , Analgésicos/uso terapéutico , Animales , Antiinflamatorios/efectos adversos , Antiinflamatorios/uso terapéutico , Edema/tratamiento farmacológico , Femenino , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Naftiridinas/efectos adversos , Naftiridinas/uso terapéutico , Ratas , Estómago/patologíaRESUMEN
BACKGROUND: 124 triazolo [4, 3-a]18naphthyridine derivatives (including NF161 and NF177) were tested for anti-inflammatory, analgesic and antipyretic properties and for their effects on spontaneous locomotor activity in mice and acute gastrolesivity in rats. Both NF161 and NF177 appeared to be anti-inflammatory and analgesic agents without toxic effects or acute gastrolesivity, but NF161 showed stronger anti-inflammatory activity, whereas NF177 was more active as analgesic. METHODS: An EIA kit was used to investigate the ability of NF161 and NF177 to affect prostaglandin E2 (PGE2) and prostacyclin (PGI2) production by human umbilical vascular endothelial cells (HUVEC). The compounds' effects on the production of reactive oxygen species (ROS) by human polymorphonuclear cells (PMNs) were studied in an in vitro cell model, evaluating inhibition of superoxide anion (O2-*) production induced by N-formylmethionyl-leucyl-phenylalanine (FMLP). Their effects on PMN adhesion to HUVEC were also investigated; they were incubated with PMNs and endothelial cells (EC) and challenged by stimuli including Platelet Activating Factor (PAF), FMLP, Phorbol Myristate Acetate (PMA), Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-1beta (IL-1beta). Adhesion was quantitated by computerized micro-imaging fluorescence analysis. RESULTS: Neither compounds modified PGE2 or PGI2 production induced by IL-1alpha. O2-* production and myeloperoxidase release from PMNs stimulated by FMLP was inhibited in a dose- but not time-dependent manner by both 18naphthyridine derivatives, NF161 being statistically more active than NF177 (P < 0.01). The compounds inhibited adhesion evoked by the pro-inflammatory stimuli PAF, FMLP, TNF-alpha and IL-1beta in a concentration-dependent manner in the 10(-6)-10(-4)M range, being more active when PAF was used as stimulus and inactive when cells were challenged by PMA. Both compounds acted both on PMN and HUVEC. CONCLUSION: Considering the interesting anti-inflammatory effects of these compounds in in vivo models and the absence of acute gastrolesivity, the study improved knowledge of anti-inflammatory properties of NF161 and NF177, also demonstrating their potential in vitro, through inhibition of O2-* production, myeloperoxidase release and PMN adhesion to HUVEC. Negative results on PG production suggest a cyclooxygenase (COX)-independent mechanism.
RESUMEN
As a further part of our chemical and biological studies in this field, we describe the multistep preparations of the properly substituted 2-(1-piperazinyl)chromone 1b, 4-(1-piperazinyl)coumarins 5c-h, their linear benzo-fused analogues 4a,b and 8a,b, bicyclic (15e-g) and tricyclic (15h,i) fused derivatives of 6-(1-piperazinyl)pyrimidin-4(3H)-one, and of the 4H-pyrido[1,2-a]pyrimidine derivatives 9b,c. The in vitro evaluation of their inhibitory properties towards human platelet aggregation induced in platelet-rich plasma by ADP, collagen, or the Ca (2+)ionophore A23187 showed the high activity of compounds 5d-g and 15f,g,i, among which the coumarins 5g and 5d proved to be, in that order, the most effective in vitro antiplatelet agents until now synthesized by us. Thus, in order to consider also the 4-aminocoumarin structural class, we developed a new statistically significant 3-D QSAR model, more general than the one previously obtained, through a further CoMFA study based on the antiplatelet activity data and molecular steric and electrostatic potentials of both the previously studied and herein described compounds.